Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the breast cancer liquid biopsy market?

In the past few years, the market size for breast cancer liquid biopsy has experienced significant growth. Projections show a surge from $0.78 billion in 2024 to $0.90 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.0%. This notable growth during the historic period can be traced back to developments in next-generation sequencing (ngs), escalating cases of breast cancer, the expanding need for non-invasive diagnostics, the swelling acceptance of personalized medicine, and enhanced funding towards cancer research.

What will be the breast cancer liquid biopsy market size in the future?

In the next few years, the market size of the breast cancer liquid biopsy is predicted to rapidly expand. It is projected to reach $1.56 billion by 2029, with a compound annual growth rate (CAGR) of 14.7%. The causes behind this predicted growth during the forecast period include advancements in liquid biopsy assay technology, an increase in the use of liquid biopsy for initial cancer screening, an escalating demand for real-time cancer monitoring, the expansion of applications in precision oncology, and an increase in investment in liquid biopsy research and development. Significant trends for the forecast period include the use of artificial intelligence in liquid biopsy analysis, breakthroughs in single-cell sequencing, the creation of multi-omics liquid biopsy platforms, enhancements in the sensitivity and specificity of liquid biopsy, and the use of digital pcr for highly accurate mutation detection.

Get your breast cancer liquid biopsy market report here!

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

What main drivers are fueling expansion in the breast cancer liquid biopsy market?

The expectant surge in breast cancer incidences is predicted to boost the expansion of the breast cancer liquid biopsy market. Breast cancer arises in the cells of the breast, commonly in the lobules (milk-producing glands) or ducts (pathways that transport milk to the nipple). The escalating number of breast cancer cases can be attributed to factors such as genetic vulnerability, hormonal disruptions, an aging population, lifestyle alterations, obesity, alcohol intake, lack of physical exercise, radiation exposure, and environmental contaminants. The utilization of a breast cancer liquid biopsy in treatment facilitates the detection of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, thereby monitoring the disease’s progression in real-time. It assists in evaluating treatment response, uncovering resistance to therapy, and pinpointing genetic alterations for targeted treatments. As an illustration, the American Cancer Society, a US-based nonprofit organization committed to cancer research, education, advocacy, and patient aid, predicts that the quantity of new breast cancer cases will escalate to 319,750 in 2025, a surge from 313,510 cases in 2024. As a result, the rising incidences of breast cancer are fueling the expansion of the breast cancer liquid biopsy market.

What key areas define the segmentation of the global breast cancer liquid biopsy market?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Who are the dominant players expanding their reach in the breast cancer liquid biopsy market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

What emerging trends are influencing the growth of the breast cancer liquid biopsy market?

Key players in the breast cancer liquid biopsy market, such as Guardant Health Inc., are making strides in the development of novel products like companion diagnostics. These innovative tools are used for personalizing treatment plans by pinpointing patients that might gain from specific treatment methods. They make use of liquid biopsy tools for the detection of biomarkers including, genetic defects, circulating tumor DNA (ctDNA), or protein markers that suggest a positive response to treatment. For instance, in January 2023, Guardant Health Inc., a leading US-based biotech firm, received the FDA’s approval for its Guardant360 CDx liquid biopsy test. It is a companion diagnostic for ORSERDU (elacestrant), a drug developed by Menarini Group for advanced or metastatic breast cancer patients who have ESR1 mutations. The go-ahead from the FDA allows oncologists to utilize the test for a thorough genomic profiling to identify patients who may get further benefits from receiving the targeted therapy. This is a landmark step for Guardant Health since it’s their first FDA approval for breast cancer, which also reinforces its position in precision oncology.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

Which regions are emerging as leaders in the breast cancer liquid biopsy market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Nanomedicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Sports Medicine Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sports-medicine-global-market-report

Natural Skin Care Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/natural-skin-care-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: